Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluvoxamine on Savolitinib Exposure
NCT05888207Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of savolitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoints: Maximum observed plasma drug concentration and Area under plasma concentration time curve from zero to infinity. Started Jun 2023; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05888207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888207.